Freenome reports 18.2% sensitivity for advanced precancerous lesions and 80.4% for colorectal cancer with its updated blood ...
Pauline M. Maki, PhD, reviews the first data cuts from OPTION-VMS, released at The Menopause Society 2025 meeting. These ...
Pauline M. Maki, PhD, introduces OPTION-VMS and explains why real-world data are needed to test whether randomized trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results